Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) priced its initial public offering in Hong Kong at the upper limit of its indicative range to raise HK$9.89 billion.
The Chinese drugmaker issued 224.5 million shares at HK$44.05 each, the top end of its guidance of as low as HK$41.45 per share, according to a Wednesday filing with the Hong Kong Exchange.
The pharmaceutical company intends to disclose the allocation results of its secondary listing on May 22, Thursday, and begin trading on the Hong Kong bourse on May 23, Friday.
The deal follows CATL's (HKG:3750, SHE:300750) over HK$35 billion share sale, reportedly the world's largest listing this year, according to Reuters.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.